Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 16/20 | 1.00 |
| ▸ | TLR4 | O00206 | 2/20 | 0.69 |
| ▸ | TLR2 | O60603 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CCR6 | P51684 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (2-Nitrovinyl)Benzene SCHEMBL28065845 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| (2-Nitrovinyl)Benzene SCHEMBL30591 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| (2-Nitrovinyl)Benzene SCHEMBL1226357 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| (2-Nitrovinyl)Benzene SCHEMBL30590 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| SCHEMBL19088017 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| (2-Nitrovinyl)Benzene SCHEMBL18132133 | 1.00 | FBP1 (1.00) | FBP1TLR4TLR2MEN1S1PR4 | |
| SCHEMBL7829071 | 0.96 | FBP1 (0.91) | FBP1TLR4TLR2MEN1S1PR4 | |
| SCHEMBL7829067 | 0.96 | FBP1 (0.91) | FBP1TLR4TLR2MEN1S1PR4 | |
| (2-Nitrovinyl)Benzene SCHEMBL28758634 | 0.94 | FBP1 (0.88) | FBP1TLR4TLR2MEN1S1PR4 | |
| Hexamethylbenzene SCHEMBL29275075 | 0.92 | FBP1 (0.84) | FBP1TLR4TLR2MEN1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372514-B | Method for catalyzing asymmetric Michael addition reaction and catalyst thereof | 常州大学 | 2022-09-27 | — | — | CN | claimed |
| CN-108727241-A | A kind of cup [4] thiocarbamide cyclohexanediamine derivative and its method for being catalyzed asymmetric Michael addition reaction | 常州大学 | 2018-11-02 | — | — | CN | claimed |
| CN-108727241-A | A kind of cup [4] thiocarbamide cyclohexanediamine derivative and its method for being catalyzed asymmetric Michael addition reaction | 常州大学 | 2018-11-02 | — | — | CN | disclosed |
| EP-2459727-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2011012632-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | HDHD5, PAH, GRHPR | FBP1 317/4885TLR4 4174/4885TLR2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.